![Dan Kirby](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 611 295 $ in data 30/06/2026
Dan Kirby currently works at Iovance Biotherapeutics, Inc., as Chief Commercial Officer from 2025.
Mr. Kirby also formerly worked at Bristol Myers Squibb Co., as Vice President & Head-US Cell in 2018, Omeros Corp., as Chief Commercial Officer from 2018 to 2020, and Orca Biosystems, Inc., as Chief Commercial Officer.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 11/05/2026 | 146.946 ( 0,03% ) | 611 295 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 10/02/2025 |
| Società | Posizione | Fine |
|---|---|---|
| OMEROS CORPORATION | Corporate Officer/Principal | 01/01/2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/09/2018 |
Orca Biosystems, Inc.
 Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Omeros Corp.
 Omeros Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes small-molecule & protein therapeutics | Health Technology |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
Orca Biosystems, Inc.
Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
